Patents by Inventor VIJAY RAMIYA
VIJAY RAMIYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200317764Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.Type: ApplicationFiled: May 8, 2020Publication date: October 8, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Patent number: 10751400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: August 26, 2019Date of Patent: August 25, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 10682401Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 1, 2017Date of Patent: June 16, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous, Michael J. Shamblott
-
Publication number: 20200000901Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: August 26, 2019Publication date: January 2, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA, MEGHAN GENTILINI
-
Patent number: 10391158Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: December 11, 2017Date of Patent: August 27, 2019Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Publication number: 20180085448Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: December 11, 2017Publication date: March 29, 2018Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 9839680Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: January 30, 2017Date of Patent: December 12, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20170232090Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 1, 2017Publication date: August 17, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Publication number: 20170136109Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: January 30, 2017Publication date: May 18, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA
-
Patent number: 9636388Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 19, 2016Date of Patent: May 2, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
-
Publication number: 20170042993Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 19, 2016Publication date: February 16, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS
-
Patent number: 9555088Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: March 4, 2015Date of Patent: January 31, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20160361400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: March 4, 2015Publication date: December 15, 2016Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA